UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Single dose escalation studies with inhaled POL6014, a potent novel selective reversible inhibitor of human neutrophil elastase, in healthy volunteers and subjects with cystic fibrosis

Journal of cystic fibrosis, 2020-03, Vol.19 (2), p.299-304

2020

Volltextzugriff (PDF)

WS01.4 A randomised, double-blind, placebo-controlled, parallel-group, dose-escalation study of inhaled single doses of POL6014, a potent and selective reversible inhibitor of human neutrophil elastase (NE), in cystic fibrosis (CF) patients

Journal of cystic fibrosis, 2017-06, Vol.16, p.S2-S2

2017

Volltextzugriff (PDF)

61 A randomised, double-blind, placebo-controlled, parallel-group, dose-escalation phase I study in healthy volunteers (HV) of inhaled single doses (SD) of POL6014, a potent and selective reversible inhibitor of human neutrophil elastase

Journal of cystic fibrosis, 2017-06, Vol.16, p.S80-S80

2017

Volltextzugriff (PDF)

A Phase Ib dose-escalation study to evaluate safety and tolerability of the addition of the aminopeptidase inhibitor tosedostat (CHR-2797) to paclitaxel in patients with advanced solid tumours

British journal of cancer, 2010-10, Vol.103 (9), p.1362-1368

2010

Volltextzugriff (PDF)

Phase I Trial of 40-kd Branched Pegylated Interferon Alfa-2a for Patients With Advanced Renal Cell Carcinoma

Journal of clinical oncology, 2001-03, Vol.19 (5), p.1312-1319

2001

Volltextzugriff (PDF)

Phase II trial of branched peginterferon-α 2a (40 kDa) for patients with advanced renal cell carcinoma

Annals of oncology, 2002-11, Vol.13 (11), p.1799-1805

2002

Volltextzugriff (PDF)

394 A phase I dose escalation and pharmacological study of the novel class I selective histone deacetylase inhibitor CHR-3996, in patients with advanced or treatment refractory solid tumours

European journal of cancer supplements, 2010, Vol.8 (7), p.125-125

2010

Volltextzugriff (PDF)

Protocol core needle biopsy and histologic Chronic Allograft Damage Index (CADI) as surrogate end point for long-term graft survival in multicenter studies

Journal of the American Society of Nephrology, 2003-03, Vol.14 (3), p.773-779

2003

Volltextzugriff (PDF)

344 POSTER A phase Ib dose escalation study to evaluate safety and tolerability of the combination of the aminopeptidase inhibitor CHR-2797 and paclitaxel in patients with advanced or treatment refractory tumors

European journal of cancer supplements, 2008, Vol.6 (12), p.109-109

2008

Volltextzugriff (PDF)

Protocol core needle biopsy and histological chronic allograft damage index as surrogate endpoint for Long-Term graft survival

Transplantation proceedings, 2004-01, Vol.36 (1), p.89-91

2004

Volltextzugriff (PDF)

A Phase I Dose Escalation and Bioequivalence Study of a Trastuzumab Biosimilar (FTMB) in Healthy Male Volunteers

Annals of oncology, 2012-09, Vol.23, p.ix103-ix104

2012

Volltextzugriff (PDF)

Phase I Evaluation of a 40-kDa Branched-Chain Long-Acting Pegylated IFN-α-2a With and Without Cytarabine in Patients with Chronic Myelogenous Leukemia

Clinical cancer research, 2005-09, Vol.11 (17), p.6247-6255

2005

Volltextzugriff (PDF)

Phase I evaluation of a 40-kDa branched-chain long-acting pegylated IFN-alpha-2a with and without cytarabine in patients with chronic myelogenous leukemia

Clinical cancer research, 2005-09, Vol.11 (17), p.6247

2005

Volltextzugriff (PDF)

A phase I pharmacokinetic (PK) and pharmacodynamic (PD) study of CHR-3996, a class 1 selective histone deacetylase inhibitor (HDACi), in patients with advanced solid tumors

Journal of clinical oncology, 2010-05, Vol.28 (15_suppl), p.2552-2552

2010

Volltextzugriff (PDF)

A Multicentre Phase II Study of the Aminopeptidase Inhibitor, CHR- 2797, in the Treatment of Elderly and/or Previously Treated patients with Acute Myeloid Leukemia

Blood, 2008-11, Vol.112 (11), p.961-961

2008

Volltextzugriff (PDF)

First in-human phase 1 trial of a novel amino-peptidase inhibitor, CHR-2797

Journal of clinical oncology, 2007-06, Vol.25 (18_suppl), p.3537-3537

2007

Volltextzugriff (PDF)

Phase II trial of branched peginterferon-alpha 2a (40 kDa) for patients with advanced renal cell carcinoma

Annals of oncology, 2002-11, Vol.13 (11), p.1799

2002

Volltextzugriff (PDF)

A phase 1 dose finding study of CHR-2797, an inhibitor of M1 aminopeptidases, in patients with advanced solid tumours

Journal of clinical oncology, 2006-06, Vol.24 (18_suppl), p.3053-3053

2006

Volltextzugriff (PDF)

Steroid withdrawal in mycophenolate mofetil-treated renal allograft recipients

Transplantation, 1997-06, Vol.63 (11), p.1688-1690

1997

Volltextzugriff (PDF)

Recognition of clonogenic leukemic cells, remission bone marrow and HLA-identical donor bone marrow by CD8+ or CD4+ minor histocompatibility antigen-specific cytotoxic T lymphocytes

The Journal of clinical investigation, 1995-08, Vol.96 (2), p.877-883

1995

Volltextzugriff (PDF)

Phase III study of liposome-encapsulated doxorubicin (TLC D-99) and cyclophosphamide (CPA) vs. epirubicin (EPI) and CPA in first-line treatment of metastatic breast cancer (MBC)

European journal of cancer (1990), 1999-09, Vol.35, p.S315-S315

1999

Volltextzugriff (PDF)

Mycophenolate mofetil in renal allograft recipients: a pooled efficacy analysis of three randomized, double-blind, clinical studies in prevention of rejection. The International Mycophenolate Mofetil Renal Transplant Study Groups

Transplantation, 1997-01, Vol.63 (1), p.39

1997

Volltextzugriff (PDF)

MYCOPHENOLATE MOFETIL IN RENAL ALLOGRAFT RECIPIENTS: A Pooled Efficacy Analysis of Three Randomized, Double-Blind, Clinical Studies in Prevention of Rejection1

Transplantation, 1997-01, Vol.63 (1), p.39-47

1997

Volltextzugriff (PDF)

Tolerability, central effects and pharmacokinetics of intravenous ketorolac tromethamine in volunteers

International journal of clinical pharmacology and therapeutics, 1994-08, Vol.32 (8), p.409

1994

Volltextzugriff (PDF)

A review of riverine ecosystem service quantification: Research gaps and recommendations

The Journal of applied ecology, 2018-05, Vol.55 (3), p.1299-1311

2018

Volltextzugriff (PDF)

1 – 25 von 64

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(61)
Mit Volltextzugriff
(55)

Publikationsform

Artikel
(63)
Bücher
(1)

Sprache

Englisch
(64)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(1)

Menü

Weitere Dienste

Einstellungen

Single dose escalation studies with inhaled POL6014, a potent novel selective reversible inhibitor of human neutrophil elastase, in healthy volunteers and subjects with cystic fibrosis

WS01.4 A randomised, double-blind, placebo-controlled, parallel-group, dose-escalation study of inhaled single doses of POL6014, a potent and selective reversible inhibitor of human neutrophil elastase (NE), in cystic fibrosis (CF) patients

61 A randomised, double-blind, placebo-controlled, parallel-group, dose-escalation phase I study in healthy volunteers (HV) of inhaled single doses (SD) of POL6014, a potent and selective reversible inhibitor of human neutrophil elastase

A Phase Ib dose-escalation study to evaluate safety and tolerability of the addition of the aminopeptidase inhibitor tosedostat (CHR-2797) to paclitaxel in patients with advanced solid tumours

Phase I Trial of 40-kd Branched Pegylated Interferon Alfa-2a for Patients With Advanced Renal Cell Carcinoma

Phase II trial of branched peginterferon-α 2a (40 kDa) for patients with advanced renal cell carcinoma

394 A phase I dose escalation and pharmacological study of the novel class I selective histone deacetylase inhibitor CHR-3996, in patients with advanced or treatment refractory solid tumours

Protocol core needle biopsy and histologic Chronic Allograft Damage Index (CADI) as surrogate end point for long-term graft survival in multicenter studies

344 POSTER A phase Ib dose escalation study to evaluate safety and tolerability of the combination of the aminopeptidase inhibitor CHR-2797 and paclitaxel in patients with advanced or treatment refractory tumors

Protocol core needle biopsy and histological chronic allograft damage index as surrogate endpoint for Long-Term graft survival

A Phase I Dose Escalation and Bioequivalence Study of a Trastuzumab Biosimilar (FTMB) in Healthy Male Volunteers

Phase I Evaluation of a 40-kDa Branched-Chain Long-Acting Pegylated IFN-α-2a With and Without Cytarabine in Patients with Chronic Myelogenous Leukemia

Phase I evaluation of a 40-kDa branched-chain long-acting pegylated IFN-alpha-2a with and without cytarabine in patients with chronic myelogenous leukemia

A phase I pharmacokinetic (PK) and pharmacodynamic (PD) study of CHR-3996, a class 1 selective histone deacetylase inhibitor (HDACi), in patients with advanced solid tumors

A Multicentre Phase II Study of the Aminopeptidase Inhibitor, CHR- 2797, in the Treatment of Elderly and/or Previously Treated patients with Acute Myeloid Leukemia

First in-human phase 1 trial of a novel amino-peptidase inhibitor, CHR-2797

Phase II trial of branched peginterferon-alpha 2a (40 kDa) for patients with advanced renal cell carcinoma

A phase 1 dose finding study of CHR-2797, an inhibitor of M1 aminopeptidases, in patients with advanced solid tumours

Steroid withdrawal in mycophenolate mofetil-treated renal allograft recipients

Recognition of clonogenic leukemic cells, remission bone marrow and HLA-identical donor bone marrow by CD8+ or CD4+ minor histocompatibility antigen-specific cytotoxic T lymphocytes

Phase III study of liposome-encapsulated doxorubicin (TLC D-99) and cyclophosphamide (CPA) vs. epirubicin (EPI) and CPA in first-line treatment of metastatic breast cancer (MBC)

Mycophenolate mofetil in renal allograft recipients: a pooled efficacy analysis of three randomized, double-blind, clinical studies in prevention of rejection. The International Mycophenolate Mofetil Renal Transplant Study Groups

MYCOPHENOLATE MOFETIL IN RENAL ALLOGRAFT RECIPIENTS: A Pooled Efficacy Analysis of Three Randomized, Double-Blind, Clinical Studies in Prevention of Rejection1

Tolerability, central effects and pharmacokinetics of intravenous ketorolac tromethamine in volunteers

A review of riverine ecosystem service quantification: Research gaps and recommendations

Suchergebnisse filtern